Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
The summit gathers leading drug developers and microbiome experts to discuss microbiome functionality, translation, clinical development, biomarker discovery, and manufacturing scale-up